R&D channel feed

Af­ter an $80M Se­ries D raise, Dal­Cor takes an­oth­er shot at a PhI­II my­ocar­dial in­farc­tion tri­al

Last year
Financing

MaaT Phar­ma and CD­MO Skyephar­ma un­veil be­spoke, and po­ten­tial­ly largest, mi­cro­bio­me fa­cil­i­ty in Eu­rope

Last year
Manufacturing

Neu­ro­crine plots 2024 fil­ing for rare dis­ease drug af­ter 'solid' PhI­II win

Last year

Eiger ends PhI­II he­pati­tis delta tri­al over safe­ty con­cerns — and the search for treat­ment part­ner

Last year

Mod­er­na CEO shares bold new vi­sion: 15 new prod­ucts and 50 new clin­i­cal can­di­dates in five years

Last year

Mironid reach­es $43.7M to date in Se­ries A ex­ten­sion to fund kid­ney dis­ease treat­ment stud­ies

Last year
Financing

WCLC roundup: As­traZeneca, Am­gen, J&J and Hutchmed tout new com­bi­na­tion or con­fir­ma­to­ry da­ta

Last year
Pharma

Ahead of ad­comm, FDA ques­tions ef­fi­ca­cy of Al­ny­lam's patisir­an in dis­abling rare con­di­tion AT­TR-CM

Last year

San Diego biotech starts clin­i­cal study of self-repli­cat­ing RNA vac­cine for ra­bies

Last year

Lyra touts pos­i­tive topline PhII da­ta for chron­ic rhi­nos­i­nusi­tis drug

Last year

Rome Ther­a­peu­tics ad­vances dark genome drug af­ter com­plet­ing $72M Se­ries B ex­ten­sion backed by Big Phar­ma

Last year
Financing

Ac­tio locks in $55M Se­ries A raise to ad­vance rare dis­ease pipeline based on hu­man ge­net­ic plat­form

Last year
Financing

Ace­lyrin's IL-17 in­hibitor fails to hit pri­ma­ry end­point in key study af­ter splashy IPO

Last year

Roche CEO out­lines new R&D strat­e­gy af­ter years of late-stage tri­al fail­ures

Last year
Pharma

Neumo­ra, Rayze­Bio look to each raise $200M+ in IPOs

Last year

Take­da says TYK2 drug it pur­chased for $4B has passed an­oth­er mid-stage test

Last year

Up­dat­ed: No­var­tis dis­con­tin­ues lead Gy­ro­scope gene ther­a­py af­ter $800M+ buy­out

Last year
Cell/Gene Tx

Gilead, As­traZeneca/Dai­ichi Sankyo of­fer first look at TROP2 AD­Cs in first-line lung can­cer as ri­val­ry heats up 

Last year

Cri­net­ics re­veals pos­i­tive topline pri­ma­ry and sec­ondary end­point da­ta in PhI­II acromegaly tri­al

Last year

As­traZeneca's Tagris­so/chemo com­bo staves off lung can­cer for al­most nine months. But will side ef­fects lim­it its use?

Last year

MIT sci­en­tists look to un­lock po­ten­tial of ‘self-ad­ju­vant­i­ng’ mR­NA vac­cines in mice

Last year
Pharma

Can No­vo Nordisk's block­buster weight loss drug and oth­er GLP-1s al­so work in NASH? The an­swer is com­pli­cat­ed

Last year
Pharma
In Focus

Al­ny­lam, Roche’s RNAi can­di­date scores mid-stage win in hy­per­ten­sion

Last year

Val­ne­va and Pfiz­er tout re­sults for the PhII of its Ly­me dis­ease vac­cine

Last year
First page Previous page 69707172737475 Next page Last page
A service from the Financial Times